Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 1, 2025

National Cancer Institute Genomics and Pharmacology Core Facility

RRID:SCR_025664
Type: Tool

Proper Citation

National Cancer Institute Genomics and Pharmacology Core Facility (RRID:SCR_025664)

Resource Information

URL: https://discover.nci.nih.gov/

Proper Citation: National Cancer Institute Genomics and Pharmacology Core Facility (RRID:SCR_025664)

Description: Provides pharmacogenomics resource for study of cancer. Multiple tools are available, currently including the CellMiner family with CellMiner, CellMinerCDB (cross database), CellMinerCDB: Small Cell Lung Cancer (SCLC), CellMinerCDB: National Center for Advancing Translational Sciences (NCATS) andCellMinerCDB: Sarcoma. These sites include multiple cancerous cell lines sets and data types. In addition there is CIMMiner for cluster image maps and MIMminer, with several scholarly molecular interaction maps.

Synonyms: Genomics and Pharmacology Facility

Resource Type: service resource, core facility, access service resource

Defining Citation: PMID:8994024

Keywords: pharmacogenomics, study of cancer, cancerous cell lines sets and data types, cluster image maps, molecular interaction maps,

Funding:

Resource Name: National Cancer Institute Genomics and Pharmacology Core Facility

Resource ID: SCR_025664

Alternate IDs: ABRF_2908

Alternate URLs: https://coremarketplace.org/?FacilityID=2908&citation=1

Record Creation Time: 20240827T053245+0000

Record Last Update: 20250501T081826+0000

Ratings and Alerts

No rating or validation information has been found for National Cancer Institute Genomics and Pharmacology Core Facility.

No alerts have been found for National Cancer Institute Genomics and Pharmacology Core Facility.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Tlemsani C, et al. (2024) Sarcoma_CellminerCDB: A tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines. iScience, 27(6), 109781.

Pommier Y, et al. (2023) New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(6), 991.

Reinhold WC, et al. (2023) CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations. Cancer research, 83(12), 1941.

Pongor LS, et al. (2022) Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation. iScience, 25(11), 105338.

Luna A, et al. (2021) CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics. Nucleic acids research, 49(D1), D1083.

Hassan R, et al. (2020) Response to Letter to the Editor by Yang et al. Journal of thoracic

oncology : official publication of the International Association for the Study of Lung Cancer, 15(6), e91.

Tlemsani C, et al. (2020) SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell reports, 33(3), 108296.

Reinhold WC, et al. (2020) Candidate biomarker assessment for pharmacological response. Translational oncology, 13(10), 100830.

Marzi L, et al. (2019) The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(20), 6206.

Reinhold WC, et al. (2019) RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB. Cancer research, 79(13), 3514.

Guo T, et al. (2019) Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. iScience, 21, 664.

Marzi L, et al. (2018) Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. Molecular cancer therapeutics, 17(8), 1694.

Rajapakse VN, et al. (2018) CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. iScience, 10, 247.

Thomas A, et al. (2017) Temozolomide in the Era of Precision Medicine. Cancer research, 77(4), 823.

Reinhold WC, et al. (2017) The NCI-60 Methylome and Its Integration into CellMiner. Cancer research, 77(3), 601.

Murai J, et al. (2016) Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget, 7(47), 76534.

Quadri M, et al. (2016) PRKRA Mutation Causing Early-Onset Generalized Dystonia-Parkinsonism (DYT16) in an Italian Family. Movement disorders : official journal of the Movement Disorder Society, 31(5), 765.

Tripathi S, et al. (2016) Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer informatics, 15, 1.

Zoppoli G, et al. (2012) CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene, 31(4), 403.

Reinhold WC, et al. (2012) CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer research, 72(14), 3499.